Apitegromab is a monoclonal antibody, not a peptide. It is included on PeptideBlog.net in the site’s related non-peptide compounds (adjunct) bucket because it comes up constantly in muscle-preservation-during-GLP-1-weight-loss discussions. It is a selective anti-myostatin antibody developed by Scholar Rock that binds the inactive precursor forms of myostatin (promyostatin and latent myostatin) without binding active myostatin, activin A, or several related TGF-beta superfamily growth factors. It was approved by the FDA in September 2026, under the brand name Isembyld, as an add-on treatment for spinal muscular atrophy (SMA). Separately, in a phase 2 trial, adding apitegromab to the GLP-1/GIP drug tirzepatide (Zepbound) preserved about 55 percent more lean mass than tirzepatide alone during weight loss; that use remains investigational and unapproved.
Not a peptide: why it is on this site
Apitegromab is a fully human monoclonal antibody, a large, engineered immune-system protein built the way therapeutic antibodies like Humira or Keytruda are built, not a short chain of amino acids synthesized the way a peptide is. It does not belong in this site’s core peptide entity model. It is documented here anyway, tagged as a related non-peptide compound in the adjunct research area, because it is frequently discussed alongside peptides such as follistatin-344 and myostatin-targeting peptides in online conversations about limiting muscle loss during GLP-1-driven weight loss, and readers searching for that topic are likely to encounter its name. Nothing in this entry should be read as classifying apitegromab as a peptide.
What is apitegromab?
Apitegromab (development code SRK-015) is a monoclonal antibody discovered and developed by Scholar Rock, a biopharmaceutical company that specializes in selectively targeting growth factors in the TGF-beta superfamily. It targets myostatin, a signaling protein that normally acts as a brake on skeletal muscle growth. Myostatin is made and secreted in an inactive form and must be cleaved by other enzymes before it becomes biologically active; apitegromab is designed to bind and lock up those inactive precursor forms so they cannot be converted into active, muscle-limiting myostatin.
The drug’s clinical development has run on two separate, unconnected tracks. The first and furthest along is spinal muscular atrophy (SMA), a rare genetic neuromuscular disease in which motor neuron loss leads to progressive muscle weakness; apitegromab was developed as an add-on to existing SMN2-targeted SMA therapies (nusinersen or risdiplam), on the premise that improving muscle quality and mass could add functional benefit on top of therapies that address the underlying genetic defect. That program produced the phase 2 TOPAZ trial and the phase 3 SAPPHIRE trial, and culminated in FDA approval in September 2026 under the brand name Isembyld (apitegromab-mstn). The second, much newer and still investigational track pairs apitegromab with GLP-1 receptor agonist weight-loss drugs, specifically tirzepatide, to test whether blocking myostatin activation can preserve lean muscle mass that is otherwise lost alongside fat during rapid GLP-1-driven weight loss. That program is called EMBRAZE and, as of this entry’s research, has completed only a phase 2 proof-of-concept trial; it is not an approved use.
How does it work?
Plain-English explanation
Muscle size is partly controlled by myostatin, a protein whose job is to put the brakes on muscle growth. The body makes myostatin in a locked, inactive form that has to be unlocked before it can act. Apitegromab works by grabbing onto that locked, inactive form and holding it shut, so less of it ever gets converted into the active brake. With less active myostatin around, the natural limit on muscle growth is loosened, which is the basis for testing it both in a muscle-wasting disease (SMA) and as a way to protect muscle during weight loss drugs that otherwise burn through muscle along with fat.
Technical explanation
Apitegromab is a fully human IgG monoclonal antibody that binds specifically to the latent and promyostatin proforms of myostatin (GDF-8), preventing their proteolytic activation into mature, signaling-competent myostatin. According to Scholar Rock’s own published mechanism description and DrugBank’s drug profile, apitegromab does not bind active (mature) myostatin, activin A, active BMP9, BMP10, or TGF-beta 1. This proform-selective, single-ligand binding profile is presented by the company as its key differentiator from earlier, broader myostatin/activin pathway inhibitors (such as bimagrumab or earlier follistatin-based approaches), which block the shared ActRII receptor and, as a result, also interfere with activin signaling. Because apitegromab acts upstream, on the precursor rather than the receptor, its developer’s rationale is that it can reduce active myostatin without broadly blocking the ActRII receptor pathway itself.
Potential benefits and research applications
Motor function in spinal muscular atrophy (SMA)
What is being investigated: whether adding apitegromab to standard SMN2-targeted SMA therapy (nusinersen or risdiplam) improves motor function beyond what those therapies achieve alone. How the effect might occur: by reducing active myostatin, apitegromab is intended to increase muscle mass and quality, which may translate into functional motor gains in patients whose underlying motor neuron disease is already being treated. Evidence: has been shown in the phase 3 SAPPHIRE trial (188 patients, ages 2 to 21, with later-onset Type 2 or Type 3 SMA on background nusinersen or risdiplam) to produce a statistically significant, reported 2.2-point improvement in Hammersmith Functional Motor Scale Expanded (HFMSE) score at one year versus placebo, with 34.2 percent of apitegromab-treated patients gaining 3 or more HFMSE points versus 13.5 percent on placebo. Strength: this is published human clinical trial evidence from a large, randomized, placebo-controlled phase 3 trial, and is the basis of FDA approval. Limitation: it is an add-on to existing SMN2 therapy, not a standalone treatment, and it was tested only in later-onset (Type 2/3), non-ambulatory patients able to sit independently, not across the full spectrum of SMA severity or age.
Lean mass preservation during GLP-1 weight loss (investigational)
What is being investigated: whether adding apitegromab to a GLP-1/GIP receptor agonist (tirzepatide) reduces the amount of lean muscle mass lost during GLP-1-driven weight loss, a widely discussed concern with this entire drug class. How the effect might occur: by reducing active myostatin during a period of caloric deficit, the hypothesis is that muscle tissue is relatively protected from the loss that otherwise accompanies rapid weight loss, even though total weight loss and fat loss may be similar. Evidence: is being investigated for this use, with one completed phase 2 proof-of-concept trial (EMBRAZE) in adults with overweight or obesity. Scholar Rock’s own press release reported that apitegromab plus tirzepatide preserved an additional 4.2 lb (1.9 kg) of lean mass, described as roughly 54.9 percent less lean-mass loss, compared with placebo plus tirzepatide, at 24 weeks (p=0.001). Strength: this is registered, published-via-press-release human phase 2 trial data with a specified p-value, not merely a repeated online claim; it corresponds closely to the approximately 55 percent figure widely discussed on forums such as r/Zepbound and r/GLP1ResearchTalk. Limitation: this is company-reported topline data from a single phase 2 trial; a full peer-reviewed publication with complete methodology and secondary endpoints was not identified at the time of this review, no phase 3 trial in this indication has been registered, and apitegromab is not approved for use alongside GLP-1 drugs or for any weight-related indication.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research, an FDA-approved label, or circulating online. Their inclusion documents what is reported and does not establish that a regimen is appropriate for any individual reader, nor does it extend approval to a use beyond the FDA-approved SMA indication.
Apitegromab has one FDA-approved dosing regimen, for SMA, and one separate phase 2 investigational regimen tested in the GLP-1 combination trial; both used the same dose and both are intravenous, not injectable-at-home or oral.
Amounts studied in human research
The approved SMA regimen and the regimen tested in the SAPPHIRE phase 3 trial is 10 mg/kg by intravenous infusion once every 4 weeks, as an add-on to background nusinersen or risdiplam therapy, in patients 2 years of age and older. The same 10 mg/kg intravenous, once-every-4-weeks regimen was used in the phase 2 EMBRAZE trial in combination with tirzepatide, over a 24-week treatment period, in adults 18 to 65 with overweight (BMI ≥27 with a weight-related comorbidity) or obesity (BMI ≥30 to ≤45), without diabetes.
Practitioner and community-reported protocols
Not consistently reported. Apitegromab is administered only by intravenous infusion in a clinical or infusion-center setting in every trial and in its approved label; this site did not identify a genuine self-administered or clinic-practitioner community dosing pattern distinct from the trial and label regimen. Community discussion on this compound (for example, on r/Zepbound and r/GLP1ResearchTalk) centers on citing and reacting to the EMBRAZE phase 2 topline results rather than reporting independent self-directed dosing, since apitegromab is not a compound obtainable or self-administered outside a clinical trial or approved prescription.
Side effects, risks, and limitations
In the SAPPHIRE phase 3 SMA trial and its extension study, apitegromab has been described by Scholar Rock and in FDA-approval press coverage as generally well tolerated, with treatment-emergent adverse events largely consistent with the underlying SMA population; a full independently tabulated adverse-event breakdown by rate was not extracted for this entry and should be confirmed against the approved FDA label before being asserted as a specific figure here. As a monoclonal antibody, class-wide risks such as infusion reactions and anti-drug antibody formation are relevant considerations; the EMBRAZE phase 2 trial monitored anti-drug antibodies against apitegromab as a prespecified secondary outcome. Because apitegromab’s SMA approval followed an earlier FDA rejection tied to manufacturing quality issues at a third-party fill-finish facility (Catalent Indiana), rather than to any safety or efficacy concern with the drug itself, that regulatory history is a manufacturing and supply consideration, not a safety signal about the molecule. For the GLP-1 combination use, it remains investigational, phase 2 only, unapproved, and long-term safety data in that population and in combination with a GLP-1 drug do not yet exist.
Regulatory and developmental status
For spinal muscular atrophy, apitegromab (brand name Isembyld, generic suffix apitegromab-mstn) was approved by the FDA on September 11, 2026, as an add-on therapy for SMA in adults and children 2 years of age and older who are already receiving an SMN2-targeted therapy (nusinersen or risdiplam). This followed an earlier, 2025 FDA rejection of Scholar Rock’s original application, attributed by reporting to manufacturing issues discovered at a third-party fill-finish facility (Catalent Indiana) during a routine inspection, not to a safety or efficacy concern with apitegromab itself; Scholar Rock resubmitted after that facility was reinspected. A regulatory decision in Europe was reported as expected around mid-2026; this entry did not independently confirm a European approval outcome and readers should treat any EU status as unconfirmed as of this review.
For the GLP-1/lean-mass-preservation use, apitegromab remains entirely investigational. It has completed one phase 2 proof-of-concept trial (EMBRAZE, NCT06445075) in combination with tirzepatide; no phase 3 trial in this population was identified as registered on ClinicalTrials.gov as of this review, and apitegromab is not approved, by the FDA or any other regulator, for any weight-management or body-composition indication.
Frequently asked questions
Is apitegromab a peptide?
No. It is a monoclonal antibody, a much larger engineered antibody protein, not a peptide. It is included on this site because it is closely tied to peptide-adjacent muscle-preservation discussions, not because it belongs to the peptide class.
What is apitegromab approved for?
Spinal muscular atrophy (SMA) in adults and children 2 years of age and older who are already on an SMN2-targeted therapy (nusinersen or risdiplam), as of FDA approval in September 2026 under the brand name Isembyld.
How does it work?
It binds and blocks the inactive precursor forms of myostatin, a protein that normally limits muscle growth, without binding active myostatin or several related growth factors, which is presented as more selective than earlier, broader myostatin/activin pathway blockers.
What dosage has been studied?
10 mg/kg by intravenous infusion once every 4 weeks, both in the SMA program (its approved regimen) and in the phase 2 GLP-1 combination trial (EMBRAZE).
Is apitegromab approved for weight loss or muscle preservation during GLP-1 use?
No. That use has only reached a completed phase 2 trial (EMBRAZE) as of this review. It is not an approved indication for apitegromab.
What did the EMBRAZE trial show?
In a phase 2 trial of 102 adults with overweight or obesity taking tirzepatide, adding apitegromab was reported by Scholar Rock to preserve about 55 percent more lean mass (an additional 4.2 lb / 1.9 kg) than tirzepatide plus placebo over 24 weeks, a statistically significant difference (p=0.001), while total weight loss and fat loss were broadly similar between groups.
What side effects have been reported?
Specific rates were not independently tabulated for this entry; reporting around the FDA approval described the SMA trial safety profile as generally consistent with the underlying disease population, with no specific efficacy or safety concern raised by the FDA (its earlier rejection concerned third-party manufacturing, not the drug). As with any monoclonal antibody, infusion reactions and anti-drug antibody formation are relevant class considerations.
What remains unknown?
Whether the EMBRAZE lean-mass results replicate in a larger, phase 3, peer-reviewed trial; whether apitegromab will ever be developed or approved for a GLP-1 combination or weight-related indication; the complete, independently tabulated adverse-event profile; and, as of this review, the final European regulatory outcome for the SMA indication.
Bottom line
Apitegromab is not a peptide, it is a monoclonal antibody, and it is documented here only because it keeps coming up in muscle-preservation-during-GLP-1 conversations. For spinal muscular atrophy, it has real phase 3 human trial evidence (SAPPHIRE) and, as of September 2026, FDA approval as Isembyld, an add-on to existing SMN2 therapy. For preserving lean mass during GLP-1-driven weight loss, it has one completed, statistically significant phase 2 trial (EMBRAZE) showing roughly 55 percent less lean-mass loss when added to tirzepatide, a figure that traces to Scholar Rock’s own primary press release rather than being an untraceable internet number, but that use remains investigational, phase 2 only, and unapproved. Readers should not treat anything in this entry as instructions, and should not assume the GLP-1 combination use will ever reach approval.